Blair William & Co. IL acquired a new position in shares of Radius Health, Inc. (NASDAQ:RDUS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 4,543 shares of the biopharmaceutical company’s stock, valued at approximately $205,000.

Other hedge funds also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. acquired a new position in Radius Health during the 1st quarter worth approximately $105,000. Sei Investments Co. increased its position in Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 690 shares in the last quarter. Envestnet Asset Management Inc. increased its position in Radius Health by 1.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock worth $163,000 after purchasing an additional 46 shares in the last quarter. Karp Capital Management Corp acquired a new position in Radius Health during the 1st quarter worth approximately $217,000. Finally, Oppenheimer Asset Management Inc. acquired a new position in Radius Health during the 1st quarter worth approximately $228,000.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/10/blair-william-co-il-takes-position-in-radius-health-inc-rdus.html.

In other Radius Health news, major shareholder Growth N. V. Biotech acquired 50,000 shares of the stock in a transaction dated Tuesday, September 5th. The stock was purchased at an average cost of $36.75 per share, for a total transaction of $1,837,500.00. Following the acquisition, the insider now owns 5,298,799 shares in the company, valued at approximately $194,730,863.25. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech acquired 150,000 shares of the stock in a transaction dated Thursday, August 10th. The stock was acquired at an average price of $34.97 per share, with a total value of $5,245,500.00. Following the completion of the acquisition, the insider now owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 260,000 shares of company stock valued at $9,241,800. Company insiders own 15.00% of the company’s stock.

A number of research firms recently issued reports on RDUS. Canaccord Genuity set a $85.00 price objective on shares of Radius Health and gave the stock a “buy” rating in a research report on Monday, July 17th. BidaskClub cut shares of Radius Health from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Cantor Fitzgerald set a $65.00 price objective on shares of Radius Health and gave the stock a “buy” rating in a research report on Monday, July 17th. HC Wainwright reiterated a “buy” rating and set a $63.00 price objective on shares of Radius Health in a research report on Monday, May 15th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $38.00 price objective (up from $34.00) on shares of Radius Health in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. Radius Health currently has an average rating of “Hold” and a consensus target price of $53.60.

Radius Health, Inc. (RDUS) opened at 36.60 on Friday. The firm has a 50-day moving average of $38.51 and a 200 day moving average of $39.43. Radius Health, Inc. has a 12 month low of $31.58 and a 12 month high of $59.22. The firm’s market capitalization is $1.59 billion.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.35) by $0.23. The firm had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $1.96 million. During the same period last year, the firm posted ($1.01) EPS. Equities research analysts forecast that Radius Health, Inc. will post ($5.58) earnings per share for the current year.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.